PEP-Therapy
Unlock cells. Deliver innovation.
LATEST NEWS
June 2nd, 2026
We are thrilled to announce that PEP-Therapy has been selected as a laureate of the Paris Saclay Cancer Cluster (PSCC) BOOST grant to support the development of its Intracellular Drug Delivery Technology (IDDT).
March 17th, 2025
PEP-Therapy receives FDA Orphan Drug Designation for PEP-010 for treatment of Pancreatic Cancer.
September 26th, 2024
We are pleased to announce the publication of our translational study in BBA – Molecular Basis of Disease, showing that our lead product, PEP-010, induces apoptosis in cancer cells, which can be monitored by pharmacodynamic biomarkers.
+ READ MORE
+ READ MORE
